Loading provider…
Loading provider…
Medical Oncology Physician in Ypsilanti, MI
NPI: 1174576219Primary Practice Location
IHA Hematology Oncology Consultants
5303 Elliott Dr, Ypsilanti, MI
Primary Employer
IHA Hematology Oncology Consultants
ihacares.com
HQ Phone
Get MD Elie's Phone NumberMobile
Get MD Elie's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardSD State Medical License
NY State Medical License
MI State Medical License
MI State Medical License
2014 - 2027
NY State Medical License
2005 - 2027
SD State Medical License
2027
MA State Medical License
2022 - 2026

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
University of Rochester Medical Center
urmc.rochester.edu
Fellowship • Hematology and Medical Oncology
2003 - 2006
Johns Hopkins University Advanced Academic Programs
Masters • Individualized Genomics and Health
2019 - 2022
Harvard Medical School
hms.harvard.edu
Post-Graduate Program • Cancer Biology & Therapeutics: High Impact Cancer Research
2018 - 2019
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 220 | 378 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 110 | 179 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 66 | 80 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 39 | 39 |
| 5 | M0010Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 34 | 159 |
Olaparib in Patients With Metastatic Prostate Cancer With/Mutation: Results From the TAPUR Study.
Authors: Mehmet Bilen, Nitin Rohatgi, Earle Burgess, Michael Zakem
Journal: JCO Precis Oncol
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Nivolumab, DRUG: Pembrolizumab, DRUG: Atezolizumab, DRUG: Avelumab, DRUG: Durvalumab
Lead Sponsor: University of Rochester NCORP Research Base
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Quality-of-Life Assessment, OTHER: Survey Administration, BEHAVIORAL: Telephone-Based Intervention, OTHER: Educational Intervention, OTHER: Behavioral, Psychological or Informational Intervention, PROCEDURE: Medical Examination Assessment
Lead Sponsor: Alliance Foundation Trials, LLC.
Collaborators: Janssen Scientific Affairs, LLC, Celgene Corporation, Takeda
Intervention / Treatment: DRUG: Lenalidomide, DRUG: Dexamethasone, DRUG: Ixazomib, DRUG: Daratumumab Injection